Barclays Sticks to Its Sell Rating for Allakos (ALLK)

In a report released today, Carter Gould from Barclays maintained a Sell rating on Allakos (ALLK – Research Report), with a price target of $1.00. The company’s shares closed yesterday at $1.29.

According to TipRanks, Gould is a 4-star analyst with an average return of 8.2% and a 54.01% success rate. Gould covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Biogen, and Regeneron.

Allakos has an analyst consensus of Hold, with a price target consensus of $3.25.

Based on Allakos’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $62.55 million. In comparison, last year the company had a GAAP net loss of $42.99 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allakos (ALLK) Company Description:

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.